Lexeo Therapeutics, Inc. (LXEO)
NASDAQ: LXEO · Real-Time Price · USD
5.81
+0.18 (3.20%)
Apr 28, 2026, 4:00 PM EDT - Market closed

Lexeo Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020
Net Income
-99.96-98.33-66.39-59.28-50.62
Upgrade
Depreciation & Amortization
2.0821.841.150.01
Upgrade
Loss (Gain) From Sale of Investments
-3.3-0.02---
Upgrade
Stock-Based Compensation
12.1312.473.041.780.39
Upgrade
Other Operating Activities
--0.53--
Upgrade
Change in Accounts Payable
-1.562.38-0.18-0.433.02
Upgrade
Change in Unearned Revenue
----0.05-0.09
Upgrade
Change in Income Taxes
----0.020.49
Upgrade
Change in Other Net Operating Assets
-7.950.351.662.292.63
Upgrade
Operating Cash Flow
-98.56-81.15-59.5-54.56-44.18
Upgrade
Capital Expenditures
-0.4-0.48-0.12-0.67-0.19
Upgrade
Sale (Purchase) of Intangibles
---0.05-0.23-
Upgrade
Investment in Securities
-89.86-93.6---
Upgrade
Investing Cash Flow
-90.25-94.08-0.17-0.9-0.19
Upgrade
Short-Term Debt Issued
--4--
Upgrade
Total Debt Issued
--4--
Upgrade
Long-Term Debt Repaid
-0.53-0.41-0.43-0.16-
Upgrade
Net Debt Issued (Repaid)
-0.53-0.413.58-0.16-
Upgrade
Issuance of Common Stock
234.0895.49100.30.330.17
Upgrade
Repurchase of Common Stock
--0.02---
Upgrade
Other Financing Activities
-16.75-6.29-0.09--0.37
Upgrade
Financing Cash Flow
216.888.78103.790.19150.86
Upgrade
Net Cash Flow
27.98-86.4544.13-55.27106.49
Upgrade
Free Cash Flow
-98.96-81.63-59.61-55.23-44.37
Upgrade
Free Cash Flow Margin
----8445.26%-2677.73%
Upgrade
Free Cash Flow Per Share
-1.84-2.57-11.13-33.88-28.58
Upgrade
Cash Interest Paid
0.10.130.180.08-
Upgrade
Levered Free Cash Flow
-62.6-48.43-35.22-33.67-25.48
Upgrade
Unlevered Free Cash Flow
-62.54-48.34-35.1-33.62-25.48
Upgrade
Change in Working Capital
-9.522.731.481.796.04
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.